Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Open-label Study of Oleclumab in Japanese Patients With Advanced Solid Malignancies
jRCT2080224133Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2018
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oleclumab in Non-hematologic malignancy, sponsored by AstraZeneca. Primary endpoints: Safety and tolerability of oleclumab, Pharmacokinetics of oleclumab and 1 more. Started Nov 2018; status: completed.
02
Drugs
oleclumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080224133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224133.